Coagulation monitor maker HemoSense prices IPO at $19.25m:
This article was originally published in Clinica
Executive Summary
HemoSense, the San Jose, California-based maker of the INRatio point-of-care device for patients taking oral anticoagulants to monitor the clotting time of their blood, has priced its initial public offering. It plans to offer 3.5 million shares at $5.50 each, for proceeds of $19.25m. Underwriters also have an option to purchase an additional 525,000 shares to cover over-allotments. The stock will be listed on the American Stock Exchange.
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.